Efficacy of bevacizumab combined with chemotherapy in the treatment of HER2-negative metastatic breast cancer: a network meta-analysis

被引：0
|
作者：
Zhengwu Sun
Xiaoyan Lan
Shizhao Xu
Shen Li
Yalin Xi
机构：
[1] Dalian Municipal Central Hospital,Department of Clinical Pharmacy
[2] Dalian Municipal Central Hospital,Department of Neurology
来源：
BMC Cancer | / 20卷
关键词：
Bevacizumab; Chemotherapy; HER2-negative metastatic breast cancer; Network meta-analysis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Efficacy of bevacizumab combined with chemotherapy in the treatment of HER2-negative metastatic breast cancer: a network meta-analysis
    Sun, Zhengwu
    Lan, Xiaoyan
    Xu, Shizhao
    Li, Shen
    Xi, Yalin
    [J]. BMC CANCER, 2020, 20 (01)
  • [2] The efficacy and safety of bevacizumab combined with chemotherapy in treatment of HER2-negative metastatic breast cancer: a meta-analysis based on published phase III trials
    Fang, Yuan
    Qu, Xinlan
    Cheng, Boran
    Chen, Yuanyuan
    Wang, Zhenmeng
    Chen, Fangfang
    Xiong, Bin
    [J]. TUMOR BIOLOGY, 2015, 36 (03) : 1933 - 1941
  • [3] SAFETY AND EFFICACY OF MAINTENANCE BEVACIZUMAB IN HER2-NEGATIVE METASTATIC BREAST CANCER
    Russillo, M.
    Metro, G.
    Giannarelli, D.
    Papaldo, P.
    Nistico, C.
    Ferretti, G.
    Cuppone, F.
    D'Auria, G.
    Cognetti, F.
    Fabi, A.
    [J]. ANNALS OF ONCOLOGY, 2010, 21 : 105 - 105
  • [4] Comparative Toxicities of Neoadjuvant Chemotherapy With or Without Bevacizumab in HER2-Negative Breast Cancer Patients: A Meta-analysis
    Wang, Bi-Cheng
    Fu, Chen
    Xie, Lin-Ka
    Kuang, Bo-Hua
    Zhao, Yan-Xia
    [J]. ANNALS OF PHARMACOTHERAPY, 2020, 54 (06) : 517 - 525
  • [5] The efficacy of bevacizumab plus paclitaxel as first-line treatment for HER2-negative metastatic breast cancer: a meta-analysis of randomized controlled trials
    Wang, Xuan
    Huang, Chun
    Li, Man
    Gu, Yanjun
    Cui, Yanfen
    Li, Yan
    [J]. TUMOR BIOLOGY, 2014, 35 (05) : 4841 - 4848
  • [6] Bevacizumab in the treatment of HER2-negative breast cancer
    Lorusso, Vito
    [J]. BIOLOGICS-TARGETS & THERAPY, 2008, 2 (04): : 813 - 821
  • [7] Neoadjuvant Chemotherapy and Bevacizumab for HER2-Negative Breast Cancer
    von Minckwitz, Gunter
    Eidtmann, Holger
    Rezai, Mahdi
    Fasching, Peter A.
    Tesch, Hans
    Eggemann, Holm
    Schrader, Iris
    Kittel, Kornelia
    Hanusch, Claus
    Kreienberg, Rolf
    Solbach, Christine
    Gerber, Bernd
    Jackisch, Christian
    Kunz, Georg
    Blohmer, Jens-Uwe
    Huober, Jens
    Hauschild, Maik
    Fehm, Tanja
    Mueller, Berit Maria
    Denkert, Carsten
    Loibl, Sibylle
    Nekljudova, Valentina
    Untch, Michael
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (04): : 299 - 309
  • [8] Bevacizumab Added to Neoadjuvant Chemotherapy in HER2-Negative Non-Metastatic Breast Cancer
    Wan, Guoxing
    Cao, Fengjun
    Wang, Xuanbin
    Sun, Xue
    [J]. JOURNAL OF CANCER, 2019, 10 (02): : 416 - 417
  • [9] Comparative Effectiveness of Taxane-Containing Regimens for Treatment of HER2-Negative Metastatic Breast Cancer: A Network Meta-analysis
    Dong, Lei
    Zhu, Li-Na
    Xie, Bao-Jie
    Li, Ji-Bin
    Ding, Tao
    Jiang, Yun-Fa
    Zhu, Zhong-Ning
    [J]. PHARMACOTHERAPY, 2019, 39 (12): : 1126 - 1136
  • [10] Metronomic Chemotherapy Combined With Bevacizumab and Erlotinib in Patients With Metastatic HER2-Negative Breast Cancer: Clinical and Biological Activity
    Montagna, Emilia
    Cancello, Giuseppe
    Bagnardi, Vincenzo
    Pastrello, Davide
    Dellapasqua, Silvia
    Perri, Gino
    Viale, Giuseppe
    Veronesi, Paolo
    Luini, Alberto
    Intra, Mattia
    Calleri, Angelica
    Rampinelli, Cristiano
    Goldhirsch, Aron
    Bertolini, Francesco
    Colleoni, Marco
    [J]. CLINICAL BREAST CANCER, 2012, 12 (03) : 207 - 214
12345